PMID: 11898536Mar 20, 2002Paper

Parkinson's disease: surgical options

Current Neurology and Neuroscience Reports
J Hammerstad, P Hogarth

Abstract

The introduction of levodopa revolutionized the treatment of Parkinson's disease. However, complications of therapy that diminish functional capacity eventually develop in the majority of patients. Studies in animal models have demonstrated that the parkinsonian state is associated with overactivity in the output nuclei of the basal ganglia. This provides a rationale for surgically targeting these nuclei to diminish this overactivity and reestablish a more balanced output (compensatory strategy). Lesioning and high-frequency stimulation of either the pallidum or the subthalamic nuclei are effective, but many questions remain regarding what surgery is best. Even more questions remain regarding the place of a restorative strategy, namely implantation of fetal midbrain tissue to replace the missing dopamine cells and "cure" the disease. Practical, ethical, and legal issues that complicate the use of human tissue have encouraged initial attempts at xenotransplantation using porcine fetal tissue.

References

Jan 1, 1992·Journal of Neurosurgery·L V LaitinenM I Hariz
Nov 1, 1996·Movement Disorders : Official Journal of the Movement Disorder Society·A BenazzouzC Gross
Dec 31, 1997·Neurology·B BejjaniY Agid
Apr 29, 1998·Brain : a Journal of Neurology·P KrackA L Benabid
Jun 5, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·J H KordowerC W Olanow
Jan 1, 1997·Stereotactic and Functional Neurosurgery·V M TronnierS Steinvorth
Oct 15, 1998·The New England Journal of Medicine·P LimousinA L Benabid
Jan 26, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·M MerelloR Leiguarda
May 13, 1999·The New England Journal of Medicine·B P BejjaniY Agid
Jun 4, 1999·Brain : a Journal of Neurology·P HagellO Lindvall
Sep 16, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·A SchragN P Quinn
Sep 24, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·C JunquéJ M Mercader
Oct 20, 1999·Journal of Neurology·A E LangA M Lozano
Feb 17, 2000·The New England Journal of Medicine·P R SchuurmanJ D Speelman
Apr 7, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·M S BaronM R DeLong
Apr 8, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·M Hallett
Jun 8, 2000·The New England Journal of Medicine·J FineA E Lang
Aug 17, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·G M RettigH S Levin
Aug 17, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·P K PalD B Calne
Sep 6, 2000·Scandinavian Journal of Immunology·L C Larsson, H Widner
Sep 29, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·J A Saint-Cyr, L L Trépanier
Dec 2, 2000·Brain : a Journal of Neurology·A KishoreS Sarma
Feb 24, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·L AlvarezJ A Obeso
Mar 10, 2001·The New England Journal of Medicine·C R FreedS Fahn

❮ Previous
Next ❯

Citations

Aug 18, 2004·Biological Psychiatry·Carsten R Bjarkam, Jens C Sørensen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

© 2022 Meta ULC. All rights reserved